Apoe (Apolipoprotein E) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Apolipoprotein E (ApoE) is a 299-amino acid glycoprotein that plays a critical role in lipid transport and neuronal repair in the central nervous system. It is encoded by the APOE gene on chromosome 19q13.32 and is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).
Apolipoprotein E (ApoE) is a polymorphic glycoprotein synthesized primarily by astrocytes and microglia in the central nervous system. As the principal lipid transport protein in the brain, ApoE facilitates the delivery of cholesterol and phospholipids to neurons via interaction with LDL receptor family members. This function is critical for maintaining neuronal membrane integrity, supporting synaptic function, and enabling neurorepair processes[1].
The APOE gene exhibits three common alleles (ε2, ε3, and ε4) that encode distinct protein isoforms differing at two amino acid positions. ApoE4, present in approximately 25% of the population, increases Alzheimer's disease risk 3-4 fold in heterozygotes and 12-15 fold in homozygotes, making it the most significant genetic risk factor for late-onset AD. Conversely, ApoE2 appears to have protective effects against AD. The mechanistic basis for these allele-specific effects involves differences in protein conformation, lipid binding affinity, and interactions with Aβ and tau pathology[2].
Beyond lipid transport, ApoE influences neuroinflammation, synaptic plasticity, and cerebrovascular function. These diverse roles explain why APOE genotype affects not only AD risk but also outcomes in traumatic brain injury, stroke, and other neurological conditions.
ApoE has a molecular weight of approximately 34 kDa and is composed of two structural domains:
The protein has three common isoforms determined by single nucleotide polymorphisms (SNPs) at positions 112 and 158:
ApoE is primarily produced by astrocytes and microglia in the brain and mediates cholesterol and phospholipid transport between neurons and glial cells[2:1]. It binds to the LDL receptor family to facilitate uptake of lipoprotein particles.
ApoE plays essential roles in:
ApoE interacts with amyloid-beta (Aβ) peptides to influence their aggregation, clearance, and deposition. It binds to Aβ with isoform-dependent affinity: ApoE4 > ApoE3 > ApoE2[4].
The APOE ε4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease:
ApoE4 promotes Aβ accumulation through several mechanisms[4:1]:
ApoE4 exacerbates tau-mediated neurodegeneration:
ApoE4 potentiates neuroinflammatory responses:
ApoE4 disrupts synaptic function:
ApoE4 affects cerebral vasculature:
Carriers of APOE ε4 show:
| Approach | Mechanism | Status |
|---|---|---|
| ApoE mimetic peptides | Promote Aβ clearance | Preclinical |
| ApoE fragment therapeutics | Receptor modulation | Phase 1 trials |
| Gene therapy | Increase ApoE2 expression | Preclinical |
| Small molecule modulators | Alter ApoE-Aβ interaction | Research |
Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537. [DOI:10.1146/annurev.genom.1.1.507^1]
Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333-344. [DOI:10.1038/nrn2620^2]
Lynch JR, et al. ApoE and the regulation of synaptic plasticity. J Neurochem. 2003;87(2):293-298. [DOI:10.1046/j.1471-4159.2003.01990.x^3]
Holtzman DM, et al. Apolipoprotein E isoform-dependent mechanisms in Alzheimer's disease. Cell. 2012;152(3):387-389. [DOI:10.1016/j.cell.2012.01.012^4]
Ridge PG, et al. Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging. 2016;41:200.e13-200.e20. [DOI:10.1016/j.neurobiolaging.2016.02.024^5]
Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523-527. [DOI:10.1038/nature24016^6]
Jack CR Jr, et al. Brain amyloid, APOE and the progression from normal cognition to MCI and AD. Neurology. 2002;59(10):1560-1568. [DOI:10.1212/01.wnl.0000035576.76584.a7^7]
The study of Apoe (Apolipoprotein E) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537. DOI:10.1146/annurev.genom.1.1.507 ↩︎ ↩︎ ↩︎
Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333-344. DOI:10.1038/nrn2620 ↩︎ ↩︎
Lynch JR, et al. ApoE and the regulation of synaptic plasticity. J Neurochem. 2003;87(2):293-298. DOI:10.1046/j.1471-4159.2003.01990.x ↩︎
Holtzman DM, et al. Apolipoprotein E isoform-dependent mechanisms in Alzheimer's disease. Cell. 2012;152(3):387-389. DOI:10.1016/j.cell.2012.01.012 ↩︎ ↩︎
Ridge PG, et al. Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging. 2016;41:200.e13-200.e20. DOI:10.1016/j.neurobiolaging.2016.02.024 ↩︎
Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523-527. DOI:10.1038/nature24016 ↩︎
Jack CR Jr, et al. Brain amyloid, APOE and the progression from normal cognition to MCI and AD. Neurology. 2002;59(10):1560-1568. DOI:10.1212/01.wnl.0000035576.76584.a7 ↩︎